| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 162.21 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Anaemia is a common complication in haemodialysis patients. This condition is
associated to a decreased bone marrow production of erythrocytes, mainly due to
the inability of the failing kidneys to secrete erythropoietin (EPO). The
introduction of recombinant human EPO (rhEPO) therapy led to a significant
reduction in anaemia and improved patients’ quality of life. However, there is a
marked variability in the sensitivity to rhEPO, with up to 10-fold variability in
dose requirements to achieve correction of anaemia. Approximately 5-10% of the
patients show a marked resistance to rhEPO therapy. rhEPO resistance is associated to an increased morbidity and mortality of haemodialysis patients. In this paper a revision of the mechanisms underlying resistance to rhEPO therapy will be performed, with particular emphasis on inflammatory cytokines, leukocyte activation, iron status, and erythrocyte damage.
Descrição
Palavras-chave
Haemodialysis Resitance to rhEPO therapy Erythropoietin Inflammation Leukocyte activation Iron status Erythrocyte damage
Contexto Educativo
Citação
COSTA, Elísio; BELO, Luís - Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage. Journal of Nephrology and Renal Transplantation. ISSN 1918-025X. Vol. 2, n.º 3 (2009), p. 66–83
Editora
OmniScientia